Items Tagged ‘News’

August 17th, 2017

Cervical Cancer Survivors Frequently Suffer From Long-Term Side Effects of Treatment

By

According to a new study around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue or hot flushes.1 Cervical cancer affects more than 500,000 women around the world each year with an average age at diagnosis of 50.  Each year in the United States, more than […]

View full entry

Tags: cancer treatment, Cervical Cancer, Chemotherapy, News, side effects


August 16th, 2017

Alternative Medicine Used Alone Appears to Reduce Survival Rates in Cancer Patients

By

Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center. The findings were reported online by the Journal of the […]

View full entry

Tags: Alternative Medicine, cancer treatment, Complementary Alternative Medicine, Complementary Medicine, News


August 14th, 2017

Head and Neck Cancer-What You Need to Know

By

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck cancers account for about 3 percent of […]

View full entry

Tags: checkpoint inhibitors, Head and Neck Cancer, human papilloma virus, keytruda, News, opdivo, PD-1, Throat Cancer


August 10th, 2017

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the Real Time IDH2 Assay, which is used to detect specific mutations in the IDH2 […]

View full entry

Tags: Acute Myeloid Leukemia, AML, Enasidenib, Idhifa, Leukemia, News


August 9th, 2017

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma

By

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. The Breakthrough Therapy Designation […]

View full entry

Tags: Acalabrutinib, Bruton tyrosine kinase, mantle cell lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


August 8th, 2017

Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers

By

Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects individuals of all ages. Its aggressiveness, rarity and diversity continue to hinder efforts to identify effective therapies for people with this malignancy. Patient-derived orthotopic xenografts (PDOX) are unique models where a patient’s individual tumor is grown in […]

View full entry

Tags: News, Precision Cancer Medicine, Sarcoma


August 7th, 2017

FDA Approves Vyxeos for Adults with Poor Prognosis AML

By

The U.S. Food and Drug Administration granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. This is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC. Approval […]

View full entry

Tags: AML liposome-encapsulated, cytarabine, daunorubicin, Myelodysplastic Syndrome, News, Vyxeos


August 2nd, 2017

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers

By

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore whether targeted therapies can be effective for children and adolescents with solid tumors that […]

View full entry

Tags: Brain Cancer, brain tumors, children with solid tumors, histiocytoses, News, non-Hodgkin lymphomas, Non-Hodgkin's Lymphoma, Pediatric MATCH trial, Precision Cancer Medicine, targeted therapy


August 1st, 2017

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence

By

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-center […]

View full entry

Tags: Breast Cancer, breast surgery, early-stage breast cancer, News, Nipple-Sparing Mastectomy


July 26th, 2017

Balance and Gait is Negatively Impacted By Chemotherapy Treatment

By

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research […]

View full entry

Tags: Balance, Breast Cancer, Chemotherapy, News, side effects


July 25th, 2017

Chimeric Antigen Receptor (CAR) T-cell Immunotherapy – Crafting a Better T Cell for Immunotherapy

By

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult B-cell Acute Lymphoblastic Leukemia.  CAR-T also shows promise in ALL, CLL, other B-cell malignancies, and other cancers. In CAR T-cell therapy, a patents immune systems T-cells are collected and reprogrammed in the laboratory to recognize and […]

View full entry

Tags: all, CAR, chimeric antigen receptor, CLL, News, nhl, Non-Hodgkin's Lymphoma, T-cell Immunotherapy


July 24th, 2017

Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas

By

Donald M. O’Rourke, MD Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat […]

View full entry

Tags: Brain Cancer, brain tumor, CAR T Cells, glioblastoma, immunotherapy, News


July 20th, 2017

Delaying Lymph Node Biopsy After Melanoma Diagnosis Does Not Affect Survival Rates

By

A lymph node biopsy occurring more than 30 days after diagnosis is unlikely to have an adverse effect on the patient’s overall prognosis Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn’t adversely impact long-term clinical outcomes according to new study findings published in the Journal of the American College of Surgeons […]

View full entry

Tags: B cell acute lymphoblastic leukemia, CAR technology, deaths, fda, Fludara, fludarabine, lymph node removal, Melanoma, News, ROCKET trial, surgery


July 19th, 2017

New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style

By

Two thirds of cancers are unavoidable even if you live a healthy life, according to a study published by doctors from John Hopkins.  The research, published in the journal Science, indicates that the majority of cancer-causing mutations are due to DNA copying errors. The recent discovery challenges the widespread belief that cancer mutations are generally inherited or triggered […]

View full entry

Tags: All Cancer Types, General, genetic risk of cancer, News, Other News Topics (not Types of Cancer), Precision Cancer Medicine


July 18th, 2017

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer

By

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the ExteNET trial (NCT00878709), a multicenter, randomized, double-blind, placebo-controlled trial of Nerlynx following adjuvant trastuzumab treatment. Women (n=2,840) with early-stage HER2-positive breast cancer […]

View full entry

Tags: Breast Cancer, HER2, neratinib, Nerlynx, News